Track Your Progress Record your weight, appetite, side effects, and injection dates
The GLP1 receptor agonist semaglutide was approved by the FDA in early 2025 for kidney disease progression in type 2 diabetics with chronic kidney disease
Previously it had only been approved for Type 1, which is the most common form and does not cause neurological symptoms
How They Work GLP-1 medications help Nocatee residents lose weight by dramatically reducing hunger and cravings (you're genuinely not hungry), slowing stomach emptying for prolonged fullness, improving insulin sensitivity and blood sugar regulation, and supporting sustainable weight loss without constant willpower battles
The Thermage procedure can take from 30 minutes to an hour, depending on the size of the treatment area
Rheumatology 2008;47:665-9